Actar AB Purchases Corning® Epic® System
Swedish Start-up Offers Label-free Drug Screening Services to European Drug Discovery Researchers
CORNING, N.Y. – Corning Incorporated (NYSE:GLW) today announced that Actar AB, a part of the Karolinska Institutet innovations system, confirmed their ability to provide label-free drug screening services via the Corning® Epic® System. Actar is the first and only company to provide high-throughput label-free drug screening to academic researchers in Scandanavia and Europe on a fee-for-service basis.
“The Corning Epic System makes us an even more powerful partner with academic institutions in developing drugs out of academic discoveries,” said Claes Post, chairman of the Actar AB Board. “We are pleased to be the first and only company to provide top European academic researchers with access to this remarkable technology.”
“Actar’s decision to purchase the Corning Epic System highlights the significant potential of label-free technology in drug discovery,” said Ron Verkleeren, business director, Corning Epic System. “We applaud Actar for developing a business model that will provide academic researchers across Scandinavia and Europe with access to this innovative new screening technology.”
The Corning Epic System is the world’s first high-throughput, label-free screening system. It uses patented optical biosensors technology to measure a broad range of biological responses that are undetectable with conventional methods.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.